nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—ABCB1—Methylprednisolone—multiple sclerosis	0.129	0.232	CbGbCtD
Nadolol—ABCB1—Mitoxantrone—multiple sclerosis	0.094	0.169	CbGbCtD
Nadolol—ABCB1—Betamethasone—multiple sclerosis	0.0838	0.151	CbGbCtD
Nadolol—ABCB1—Prednisolone—multiple sclerosis	0.0827	0.149	CbGbCtD
Nadolol—ABCB1—Prednisone—multiple sclerosis	0.0781	0.141	CbGbCtD
Nadolol—ABCB1—Dexamethasone—multiple sclerosis	0.0487	0.0878	CbGbCtD
Nadolol—ABCB1—Methotrexate—multiple sclerosis	0.0392	0.0705	CbGbCtD
Nadolol—Abdominal distension—Methylprednisolone—multiple sclerosis	0.00106	0.00273	CcSEcCtD
Nadolol—Irritability—Dexamethasone—multiple sclerosis	0.00106	0.00272	CcSEcCtD
Nadolol—Irritability—Betamethasone—multiple sclerosis	0.00106	0.00272	CcSEcCtD
Nadolol—Decreased appetite—Cladribine—multiple sclerosis	0.00105	0.00271	CcSEcCtD
Nadolol—Mood swings—Dexamethasone—multiple sclerosis	0.00105	0.0027	CcSEcCtD
Nadolol—Mood swings—Betamethasone—multiple sclerosis	0.00105	0.0027	CcSEcCtD
Nadolol—Weight increased—Prednisolone—multiple sclerosis	0.00105	0.00269	CcSEcCtD
Nadolol—Fatigue—Cladribine—multiple sclerosis	0.00104	0.00269	CcSEcCtD
Nadolol—Bronchospasm—Methylprednisolone—multiple sclerosis	0.00104	0.00267	CcSEcCtD
Nadolol—Constipation—Cladribine—multiple sclerosis	0.00104	0.00267	CcSEcCtD
Nadolol—Pain—Cladribine—multiple sclerosis	0.00104	0.00267	CcSEcCtD
Nadolol—Amnesia—Prednisone—multiple sclerosis	0.00103	0.00265	CcSEcCtD
Nadolol—Dry skin—Dexamethasone—multiple sclerosis	0.00102	0.00262	CcSEcCtD
Nadolol—Dry skin—Betamethasone—multiple sclerosis	0.00102	0.00262	CcSEcCtD
Nadolol—Conjunctivitis—Prednisolone—multiple sclerosis	0.000996	0.00256	CcSEcCtD
Nadolol—Alopecia—Mitoxantrone—multiple sclerosis	0.000991	0.00255	CcSEcCtD
Nadolol—Pulmonary oedema—Methotrexate—multiple sclerosis	0.00099	0.00255	CcSEcCtD
Nadolol—Cardiac failure—Prednisone—multiple sclerosis	0.00099	0.00255	CcSEcCtD
Nadolol—Lethargy—Prednisone—multiple sclerosis	0.000986	0.00254	CcSEcCtD
Nadolol—Weight increased—Triamcinolone—multiple sclerosis	0.000962	0.00247	CcSEcCtD
Nadolol—Weight increased—Methylprednisolone—multiple sclerosis	0.000959	0.00247	CcSEcCtD
Nadolol—Body temperature increased—Cladribine—multiple sclerosis	0.000958	0.00247	CcSEcCtD
Nadolol—Affect lability—Prednisone—multiple sclerosis	0.000951	0.00245	CcSEcCtD
Nadolol—Bradycardia—Prednisolone—multiple sclerosis	0.000936	0.00241	CcSEcCtD
Nadolol—Irritability—Prednisone—multiple sclerosis	0.000922	0.00237	CcSEcCtD
Nadolol—Hypotension—Azathioprine—multiple sclerosis	0.000921	0.00237	CcSEcCtD
Nadolol—Vision blurred—Mitoxantrone—multiple sclerosis	0.00092	0.00237	CcSEcCtD
Nadolol—Conjunctivitis—Triamcinolone—multiple sclerosis	0.000916	0.00236	CcSEcCtD
Nadolol—Mood swings—Prednisone—multiple sclerosis	0.000915	0.00236	CcSEcCtD
Nadolol—Sweating—Methylprednisolone—multiple sclerosis	0.000901	0.00232	CcSEcCtD
Nadolol—Visual impairment—Prednisolone—multiple sclerosis	0.000886	0.00228	CcSEcCtD
Nadolol—Dry skin—Prednisone—multiple sclerosis	0.000885	0.00228	CcSEcCtD
Nadolol—Weight increased—Dexamethasone—multiple sclerosis	0.000872	0.00225	CcSEcCtD
Nadolol—Weight increased—Betamethasone—multiple sclerosis	0.000872	0.00225	CcSEcCtD
Nadolol—Asthenia—Cladribine—multiple sclerosis	0.000869	0.00224	CcSEcCtD
Nadolol—Bradycardia—Triamcinolone—multiple sclerosis	0.000861	0.00222	CcSEcCtD
Nadolol—Bradycardia—Methylprednisolone—multiple sclerosis	0.000859	0.00221	CcSEcCtD
Nadolol—Pruritus—Cladribine—multiple sclerosis	0.000857	0.00221	CcSEcCtD
Nadolol—Visual disturbance—Methotrexate—multiple sclerosis	0.000852	0.00219	CcSEcCtD
Nadolol—Cough—Mitoxantrone—multiple sclerosis	0.000852	0.00219	CcSEcCtD
Nadolol—Hypertension—Mitoxantrone—multiple sclerosis	0.000842	0.00217	CcSEcCtD
Nadolol—Abdominal distension—Prednisone—multiple sclerosis	0.000841	0.00216	CcSEcCtD
Nadolol—Hallucination—Methylprednisolone—multiple sclerosis	0.00084	0.00216	CcSEcCtD
Nadolol—Conjunctivitis—Dexamethasone—multiple sclerosis	0.000831	0.00214	CcSEcCtD
Nadolol—Conjunctivitis—Betamethasone—multiple sclerosis	0.000831	0.00214	CcSEcCtD
Nadolol—Chest pain—Mitoxantrone—multiple sclerosis	0.000831	0.00214	CcSEcCtD
Nadolol—Diarrhoea—Cladribine—multiple sclerosis	0.000829	0.00213	CcSEcCtD
Nadolol—Lethargy—Methotrexate—multiple sclerosis	0.000824	0.00212	CcSEcCtD
Nadolol—Visual impairment—Methylprednisolone—multiple sclerosis	0.000813	0.00209	CcSEcCtD
Nadolol—Dizziness—Cladribine—multiple sclerosis	0.000801	0.00206	CcSEcCtD
Nadolol—Oedema—Mitoxantrone—multiple sclerosis	0.000796	0.00205	CcSEcCtD
Nadolol—Shock—Mitoxantrone—multiple sclerosis	0.000784	0.00202	CcSEcCtD
Nadolol—Bradycardia—Dexamethasone—multiple sclerosis	0.000781	0.00201	CcSEcCtD
Nadolol—Bradycardia—Betamethasone—multiple sclerosis	0.000781	0.00201	CcSEcCtD
Nadolol—Body temperature increased—Azathioprine—multiple sclerosis	0.000779	0.002	CcSEcCtD
Nadolol—Irritability—Methotrexate—multiple sclerosis	0.000771	0.00198	CcSEcCtD
Nadolol—Vomiting—Cladribine—multiple sclerosis	0.00077	0.00198	CcSEcCtD
Nadolol—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00077	0.00198	CcSEcCtD
Nadolol—Erectile dysfunction—Prednisone—multiple sclerosis	0.000769	0.00198	CcSEcCtD
Nadolol—Mood swings—Methotrexate—multiple sclerosis	0.000765	0.00197	CcSEcCtD
Nadolol—Rash—Cladribine—multiple sclerosis	0.000764	0.00197	CcSEcCtD
Nadolol—Hallucination—Dexamethasone—multiple sclerosis	0.000764	0.00197	CcSEcCtD
Nadolol—Hallucination—Betamethasone—multiple sclerosis	0.000764	0.00197	CcSEcCtD
Nadolol—Dermatitis—Cladribine—multiple sclerosis	0.000763	0.00196	CcSEcCtD
Nadolol—Weight increased—Prednisone—multiple sclerosis	0.00076	0.00196	CcSEcCtD
Nadolol—Anorexia—Mitoxantrone—multiple sclerosis	0.000759	0.00195	CcSEcCtD
Nadolol—Vision blurred—Prednisolone—multiple sclerosis	0.000754	0.00194	CcSEcCtD
Nadolol—Hypotension—Mitoxantrone—multiple sclerosis	0.000744	0.00192	CcSEcCtD
Nadolol—Depression—Prednisone—multiple sclerosis	0.000742	0.00191	CcSEcCtD
Nadolol—Visual impairment—Betamethasone—multiple sclerosis	0.00074	0.0019	CcSEcCtD
Nadolol—Visual impairment—Dexamethasone—multiple sclerosis	0.00074	0.0019	CcSEcCtD
Nadolol—Nausea—Cladribine—multiple sclerosis	0.00072	0.00185	CcSEcCtD
Nadolol—Syncope—Prednisolone—multiple sclerosis	0.000718	0.00185	CcSEcCtD
Nadolol—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000715	0.00184	CcSEcCtD
Nadolol—Dyspnoea—Mitoxantrone—multiple sclerosis	0.00071	0.00183	CcSEcCtD
Nadolol—Loss of consciousness—Prednisolone—multiple sclerosis	0.000704	0.00181	CcSEcCtD
Nadolol—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000701	0.0018	CcSEcCtD
Nadolol—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000692	0.00178	CcSEcCtD
Nadolol—Hypertension—Prednisolone—multiple sclerosis	0.000691	0.00178	CcSEcCtD
Nadolol—Fatigue—Mitoxantrone—multiple sclerosis	0.000687	0.00177	CcSEcCtD
Nadolol—Constipation—Mitoxantrone—multiple sclerosis	0.000681	0.00175	CcSEcCtD
Nadolol—Pain—Mitoxantrone—multiple sclerosis	0.000681	0.00175	CcSEcCtD
Nadolol—Bradycardia—Prednisone—multiple sclerosis	0.00068	0.00175	CcSEcCtD
Nadolol—Alopecia—Dexamethasone—multiple sclerosis	0.000678	0.00175	CcSEcCtD
Nadolol—Alopecia—Betamethasone—multiple sclerosis	0.000678	0.00175	CcSEcCtD
Nadolol—Diarrhoea—Azathioprine—multiple sclerosis	0.000674	0.00173	CcSEcCtD
Nadolol—Abdominal discomfort—Methotrexate—multiple sclerosis	0.000669	0.00172	CcSEcCtD
Nadolol—Hallucination—Prednisone—multiple sclerosis	0.000665	0.00171	CcSEcCtD
Nadolol—Syncope—Triamcinolone—multiple sclerosis	0.00066	0.0017	CcSEcCtD
Nadolol—Syncope—Methylprednisolone—multiple sclerosis	0.000659	0.0017	CcSEcCtD
Nadolol—Oedema—Prednisolone—multiple sclerosis	0.000653	0.00168	CcSEcCtD
Nadolol—Dizziness—Azathioprine—multiple sclerosis	0.000651	0.00168	CcSEcCtD
Nadolol—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000647	0.00167	CcSEcCtD
Nadolol—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000646	0.00166	CcSEcCtD
Nadolol—Shock—Prednisolone—multiple sclerosis	0.000643	0.00165	CcSEcCtD
Nadolol—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000643	0.00165	CcSEcCtD
Nadolol—Cough—Triamcinolone—multiple sclerosis	0.000642	0.00165	CcSEcCtD
Nadolol—Hypertension—Triamcinolone—multiple sclerosis	0.000636	0.00164	CcSEcCtD
Nadolol—Hypertension—Methylprednisolone—multiple sclerosis	0.000634	0.00163	CcSEcCtD
Nadolol—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000632	0.00163	CcSEcCtD
Nadolol—Body temperature increased—Mitoxantrone—multiple sclerosis	0.00063	0.00162	CcSEcCtD
Nadolol—Vomiting—Azathioprine—multiple sclerosis	0.000626	0.00161	CcSEcCtD
Nadolol—Rash—Azathioprine—multiple sclerosis	0.000621	0.0016	CcSEcCtD
Nadolol—Dermatitis—Azathioprine—multiple sclerosis	0.000621	0.0016	CcSEcCtD
Nadolol—Depression—Methotrexate—multiple sclerosis	0.00062	0.0016	CcSEcCtD
Nadolol—Dry mouth—Triamcinolone—multiple sclerosis	0.000613	0.00158	CcSEcCtD
Nadolol—Conjunctivitis—Methotrexate—multiple sclerosis	0.000605	0.00156	CcSEcCtD
Nadolol—Oedema—Triamcinolone—multiple sclerosis	0.000601	0.00155	CcSEcCtD
Nadolol—Syncope—Dexamethasone—multiple sclerosis	0.000599	0.00154	CcSEcCtD
Nadolol—Syncope—Betamethasone—multiple sclerosis	0.000599	0.00154	CcSEcCtD
Nadolol—Sweating—Methotrexate—multiple sclerosis	0.000596	0.00154	CcSEcCtD
Nadolol—Shock—Triamcinolone—multiple sclerosis	0.000591	0.00152	CcSEcCtD
Nadolol—Insomnia—Prednisolone—multiple sclerosis	0.000591	0.00152	CcSEcCtD
Nadolol—Alopecia—Prednisone—multiple sclerosis	0.000591	0.00152	CcSEcCtD
Nadolol—Shock—Methylprednisolone—multiple sclerosis	0.00059	0.00152	CcSEcCtD
Nadolol—Loss of consciousness—Betamethasone—multiple sclerosis	0.000587	0.00151	CcSEcCtD
Nadolol—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000587	0.00151	CcSEcCtD
Nadolol—Paraesthesia—Prednisolone—multiple sclerosis	0.000587	0.00151	CcSEcCtD
Nadolol—Nausea—Azathioprine—multiple sclerosis	0.000585	0.00151	CcSEcCtD
Nadolol—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000581	0.00149	CcSEcCtD
Nadolol—Agranulocytosis—Methotrexate—multiple sclerosis	0.000581	0.00149	CcSEcCtD
Nadolol—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.00058	0.00149	CcSEcCtD
Nadolol—Hypertension—Dexamethasone—multiple sclerosis	0.000577	0.00148	CcSEcCtD
Nadolol—Hypertension—Betamethasone—multiple sclerosis	0.000577	0.00148	CcSEcCtD
Nadolol—Asthenia—Mitoxantrone—multiple sclerosis	0.000571	0.00147	CcSEcCtD
Nadolol—Hypotension—Methylprednisolone—multiple sclerosis	0.00056	0.00144	CcSEcCtD
Nadolol—Pain—Prednisolone—multiple sclerosis	0.000559	0.00144	CcSEcCtD
Nadolol—Vision blurred—Prednisone—multiple sclerosis	0.000548	0.00141	CcSEcCtD
Nadolol—Oedema—Dexamethasone—multiple sclerosis	0.000545	0.0014	CcSEcCtD
Nadolol—Oedema—Betamethasone—multiple sclerosis	0.000545	0.0014	CcSEcCtD
Nadolol—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000545	0.0014	CcSEcCtD
Nadolol—Insomnia—Triamcinolone—multiple sclerosis	0.000543	0.0014	CcSEcCtD
Nadolol—Insomnia—Methylprednisolone—multiple sclerosis	0.000542	0.0014	CcSEcCtD
Nadolol—Paraesthesia—Triamcinolone—multiple sclerosis	0.00054	0.00139	CcSEcCtD
Nadolol—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000538	0.00139	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—multiple sclerosis	0.000538	0.00139	CcSEcCtD
Nadolol—Shock—Dexamethasone—multiple sclerosis	0.000536	0.00138	CcSEcCtD
Nadolol—Shock—Betamethasone—multiple sclerosis	0.000536	0.00138	CcSEcCtD
Nadolol—Dyspnoea—Triamcinolone—multiple sclerosis	0.000536	0.00138	CcSEcCtD
Nadolol—Dyspepsia—Triamcinolone—multiple sclerosis	0.000529	0.00136	CcSEcCtD
Nadolol—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000528	0.00136	CcSEcCtD
Nadolol—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000527	0.00136	CcSEcCtD
Nadolol—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000527	0.00136	CcSEcCtD
Nadolol—Syncope—Prednisone—multiple sclerosis	0.000522	0.00134	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—multiple sclerosis	0.000521	0.00134	CcSEcCtD
Nadolol—Anorexia—Betamethasone—multiple sclerosis	0.00052	0.00134	CcSEcCtD
Nadolol—Anorexia—Dexamethasone—multiple sclerosis	0.00052	0.00134	CcSEcCtD
Nadolol—Fatigue—Triamcinolone—multiple sclerosis	0.000518	0.00133	CcSEcCtD
Nadolol—Fatigue—Methylprednisolone—multiple sclerosis	0.000517	0.00133	CcSEcCtD
Nadolol—Pain—Triamcinolone—multiple sclerosis	0.000514	0.00132	CcSEcCtD
Nadolol—Loss of consciousness—Prednisone—multiple sclerosis	0.000511	0.00132	CcSEcCtD
Nadolol—Hypotension—Dexamethasone—multiple sclerosis	0.000509	0.00131	CcSEcCtD
Nadolol—Hypotension—Betamethasone—multiple sclerosis	0.000509	0.00131	CcSEcCtD
Nadolol—Vomiting—Mitoxantrone—multiple sclerosis	0.000506	0.0013	CcSEcCtD
Nadolol—Hypertension—Prednisone—multiple sclerosis	0.000502	0.00129	CcSEcCtD
Nadolol—Rash—Mitoxantrone—multiple sclerosis	0.000502	0.00129	CcSEcCtD
Nadolol—Dermatitis—Mitoxantrone—multiple sclerosis	0.000502	0.00129	CcSEcCtD
Nadolol—Alopecia—Methotrexate—multiple sclerosis	0.000494	0.00127	CcSEcCtD
Nadolol—Insomnia—Betamethasone—multiple sclerosis	0.000493	0.00127	CcSEcCtD
Nadolol—Insomnia—Dexamethasone—multiple sclerosis	0.000493	0.00127	CcSEcCtD
Nadolol—Paraesthesia—Betamethasone—multiple sclerosis	0.00049	0.00126	CcSEcCtD
Nadolol—Paraesthesia—Dexamethasone—multiple sclerosis	0.00049	0.00126	CcSEcCtD
Nadolol—Dyspepsia—Betamethasone—multiple sclerosis	0.00048	0.00124	CcSEcCtD
Nadolol—Dyspepsia—Dexamethasone—multiple sclerosis	0.00048	0.00124	CcSEcCtD
Nadolol—Body temperature increased—Triamcinolone—multiple sclerosis	0.000475	0.00122	CcSEcCtD
Nadolol—Oedema—Prednisone—multiple sclerosis	0.000475	0.00122	CcSEcCtD
Nadolol—Decreased appetite—Dexamethasone—multiple sclerosis	0.000474	0.00122	CcSEcCtD
Nadolol—Decreased appetite—Betamethasone—multiple sclerosis	0.000474	0.00122	CcSEcCtD
Nadolol—Nausea—Mitoxantrone—multiple sclerosis	0.000473	0.00122	CcSEcCtD
Nadolol—Fatigue—Dexamethasone—multiple sclerosis	0.00047	0.00121	CcSEcCtD
Nadolol—Fatigue—Betamethasone—multiple sclerosis	0.00047	0.00121	CcSEcCtD
Nadolol—Shock—Prednisone—multiple sclerosis	0.000467	0.0012	CcSEcCtD
Nadolol—Pain—Betamethasone—multiple sclerosis	0.000466	0.0012	CcSEcCtD
Nadolol—Pain—Dexamethasone—multiple sclerosis	0.000466	0.0012	CcSEcCtD
Nadolol—Hyperhidrosis—Prednisone—multiple sclerosis	0.000459	0.00118	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—multiple sclerosis	0.000458	0.00118	CcSEcCtD
Nadolol—Anorexia—Prednisone—multiple sclerosis	0.000453	0.00116	CcSEcCtD
Nadolol—Dizziness—Prednisolone—multiple sclerosis	0.000432	0.00111	CcSEcCtD
Nadolol—Asthenia—Triamcinolone—multiple sclerosis	0.000431	0.00111	CcSEcCtD
Nadolol—Body temperature increased—Betamethasone—multiple sclerosis	0.000431	0.00111	CcSEcCtD
Nadolol—Body temperature increased—Dexamethasone—multiple sclerosis	0.000431	0.00111	CcSEcCtD
Nadolol—Asthenia—Methylprednisolone—multiple sclerosis	0.00043	0.00111	CcSEcCtD
Nadolol—Insomnia—Prednisone—multiple sclerosis	0.000429	0.00111	CcSEcCtD
Nadolol—Paraesthesia—Prednisone—multiple sclerosis	0.000426	0.0011	CcSEcCtD
Nadolol—Pruritus—Triamcinolone—multiple sclerosis	0.000425	0.00109	CcSEcCtD
Nadolol—Cough—Methotrexate—multiple sclerosis	0.000424	0.00109	CcSEcCtD
Nadolol—Pruritus—Methylprednisolone—multiple sclerosis	0.000424	0.00109	CcSEcCtD
Nadolol—Dyspepsia—Prednisone—multiple sclerosis	0.000418	0.00108	CcSEcCtD
Nadolol—Chest pain—Methotrexate—multiple sclerosis	0.000414	0.00107	CcSEcCtD
Nadolol—Decreased appetite—Prednisone—multiple sclerosis	0.000413	0.00106	CcSEcCtD
Nadolol—Rash—Prednisolone—multiple sclerosis	0.000412	0.00106	CcSEcCtD
Nadolol—Dermatitis—Prednisolone—multiple sclerosis	0.000412	0.00106	CcSEcCtD
Nadolol—Diarrhoea—Methylprednisolone—multiple sclerosis	0.00041	0.00106	CcSEcCtD
Nadolol—Fatigue—Prednisone—multiple sclerosis	0.000409	0.00105	CcSEcCtD
Nadolol—Constipation—Prednisone—multiple sclerosis	0.000406	0.00104	CcSEcCtD
Nadolol—Dizziness—Triamcinolone—multiple sclerosis	0.000397	0.00102	CcSEcCtD
Nadolol—Dizziness—Methylprednisolone—multiple sclerosis	0.000396	0.00102	CcSEcCtD
Nadolol—Asthenia—Betamethasone—multiple sclerosis	0.000391	0.00101	CcSEcCtD
Nadolol—Asthenia—Dexamethasone—multiple sclerosis	0.000391	0.00101	CcSEcCtD
Nadolol—Nausea—Prednisolone—multiple sclerosis	0.000388	0.000999	CcSEcCtD
Nadolol—Pruritus—Betamethasone—multiple sclerosis	0.000386	0.000993	CcSEcCtD
Nadolol—Pruritus—Dexamethasone—multiple sclerosis	0.000386	0.000993	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000384	0.000987	CcSEcCtD
Nadolol—Vomiting—Triamcinolone—multiple sclerosis	0.000382	0.000983	CcSEcCtD
Nadolol—Vomiting—Methylprednisolone—multiple sclerosis	0.000381	0.000981	CcSEcCtD
Nadolol—Rash—Triamcinolone—multiple sclerosis	0.000379	0.000975	CcSEcCtD
Nadolol—Dermatitis—Triamcinolone—multiple sclerosis	0.000378	0.000974	CcSEcCtD
Nadolol—Anorexia—Methotrexate—multiple sclerosis	0.000378	0.000973	CcSEcCtD
Nadolol—Rash—Methylprednisolone—multiple sclerosis	0.000378	0.000973	CcSEcCtD
Nadolol—Dermatitis—Methylprednisolone—multiple sclerosis	0.000378	0.000972	CcSEcCtD
Nadolol—Body temperature increased—Prednisone—multiple sclerosis	0.000375	0.000966	CcSEcCtD
Nadolol—Diarrhoea—Betamethasone—multiple sclerosis	0.000373	0.00096	CcSEcCtD
Nadolol—Diarrhoea—Dexamethasone—multiple sclerosis	0.000373	0.00096	CcSEcCtD
Nadolol—Hypotension—Methotrexate—multiple sclerosis	0.000371	0.000954	CcSEcCtD
Nadolol—Dizziness—Dexamethasone—multiple sclerosis	0.000361	0.000928	CcSEcCtD
Nadolol—Dizziness—Betamethasone—multiple sclerosis	0.000361	0.000928	CcSEcCtD
Nadolol—Insomnia—Methotrexate—multiple sclerosis	0.000359	0.000924	CcSEcCtD
Nadolol—Nausea—Triamcinolone—multiple sclerosis	0.000357	0.000919	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—multiple sclerosis	0.000356	0.000917	CcSEcCtD
Nadolol—Nausea—Methylprednisolone—multiple sclerosis	0.000356	0.000916	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—multiple sclerosis	0.000354	0.00091	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—multiple sclerosis	0.000349	0.000899	CcSEcCtD
Nadolol—Vomiting—Dexamethasone—multiple sclerosis	0.000347	0.000892	CcSEcCtD
Nadolol—Vomiting—Betamethasone—multiple sclerosis	0.000347	0.000892	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—multiple sclerosis	0.000345	0.000888	CcSEcCtD
Nadolol—Rash—Dexamethasone—multiple sclerosis	0.000344	0.000885	CcSEcCtD
Nadolol—Rash—Betamethasone—multiple sclerosis	0.000344	0.000885	CcSEcCtD
Nadolol—Dermatitis—Dexamethasone—multiple sclerosis	0.000343	0.000884	CcSEcCtD
Nadolol—Dermatitis—Betamethasone—multiple sclerosis	0.000343	0.000884	CcSEcCtD
Nadolol—Fatigue—Methotrexate—multiple sclerosis	0.000342	0.00088	CcSEcCtD
Nadolol—Asthenia—Prednisone—multiple sclerosis	0.000341	0.000877	CcSEcCtD
Nadolol—Pain—Methotrexate—multiple sclerosis	0.000339	0.000873	CcSEcCtD
Nadolol—Pruritus—Prednisone—multiple sclerosis	0.000336	0.000865	CcSEcCtD
Nadolol—Diarrhoea—Prednisone—multiple sclerosis	0.000325	0.000836	CcSEcCtD
Nadolol—Nausea—Dexamethasone—multiple sclerosis	0.000324	0.000833	CcSEcCtD
Nadolol—Nausea—Betamethasone—multiple sclerosis	0.000324	0.000833	CcSEcCtD
Nadolol—Dizziness—Prednisone—multiple sclerosis	0.000314	0.000808	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—multiple sclerosis	0.000314	0.000807	CcSEcCtD
Nadolol—Vomiting—Prednisone—multiple sclerosis	0.000302	0.000777	CcSEcCtD
Nadolol—Rash—Prednisone—multiple sclerosis	0.000299	0.00077	CcSEcCtD
Nadolol—Dermatitis—Prednisone—multiple sclerosis	0.000299	0.00077	CcSEcCtD
Nadolol—Asthenia—Methotrexate—multiple sclerosis	0.000285	0.000733	CcSEcCtD
Nadolol—Nausea—Prednisone—multiple sclerosis	0.000282	0.000726	CcSEcCtD
Nadolol—Pruritus—Methotrexate—multiple sclerosis	0.000281	0.000722	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—multiple sclerosis	0.000271	0.000699	CcSEcCtD
Nadolol—Dizziness—Methotrexate—multiple sclerosis	0.000262	0.000675	CcSEcCtD
Nadolol—Vomiting—Methotrexate—multiple sclerosis	0.000252	0.000649	CcSEcCtD
Nadolol—Rash—Methotrexate—multiple sclerosis	0.00025	0.000644	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—multiple sclerosis	0.00025	0.000643	CcSEcCtD
Nadolol—Nausea—Methotrexate—multiple sclerosis	0.000236	0.000607	CcSEcCtD
Nadolol—ADRB3—GPCR ligand binding—CCR5—multiple sclerosis	0.000143	0.00254	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL3—multiple sclerosis	0.000142	0.00253	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—S1PR1—multiple sclerosis	0.000142	0.00253	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—S1PR1—multiple sclerosis	0.000141	0.00252	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.00014	0.0025	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—PTGER4—multiple sclerosis	0.00014	0.00249	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—S1PR1—multiple sclerosis	0.000139	0.00247	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GPC5—multiple sclerosis	0.000138	0.00245	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—PTGER4—multiple sclerosis	0.000137	0.00244	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCR3—multiple sclerosis	0.000135	0.00241	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—PTGER4—multiple sclerosis	0.000133	0.00237	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—RGS1—multiple sclerosis	0.000133	0.00237	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCR3—multiple sclerosis	0.000132	0.00235	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCR2—multiple sclerosis	0.000132	0.00234	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—RGS1—multiple sclerosis	0.00013	0.00231	CbGpPWpGaD
Nadolol—ADRB1—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.00013	0.00231	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCR3—multiple sclerosis	0.000129	0.00229	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCR2—multiple sclerosis	0.000129	0.00229	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000127	0.00227	CbGpPWpGaD
Nadolol—ADRB2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000127	0.00226	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—GPR65—multiple sclerosis	0.000126	0.00224	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL3—multiple sclerosis	0.000126	0.00224	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CCR2—multiple sclerosis	0.000125	0.00223	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000124	0.0022	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000124	0.0022	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—GPR65—multiple sclerosis	0.000123	0.00219	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CNR1—multiple sclerosis	0.000121	0.00216	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—PTGER4—multiple sclerosis	0.000121	0.00215	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	0.000121	0.00215	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—RGS1—multiple sclerosis	0.000121	0.00215	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—RGS1—multiple sclerosis	0.00012	0.00214	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CNR1—multiple sclerosis	0.000119	0.00211	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—RGS1—multiple sclerosis	0.000118	0.0021	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCR3—multiple sclerosis	0.000117	0.00208	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CNR1—multiple sclerosis	0.000116	0.00206	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000115	0.00205	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCR1—multiple sclerosis	0.000115	0.00205	CbGpPWpGaD
Nadolol—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	0.000115	0.00205	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—GPR65—multiple sclerosis	0.000115	0.00204	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—GPR65—multiple sclerosis	0.000114	0.00203	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCR2—multiple sclerosis	0.000114	0.00202	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	0.000113	0.00201	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL13—multiple sclerosis	0.000113	0.00201	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCR1—multiple sclerosis	0.000113	0.00201	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—GPR65—multiple sclerosis	0.000112	0.00199	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—POMC—multiple sclerosis	0.000112	0.00199	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000111	0.00198	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—LINGO1—multiple sclerosis	0.000111	0.00197	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CXCL10—multiple sclerosis	0.000109	0.00194	CbGpPWpGaD
Nadolol—ADRB3—GPCR ligand binding—CCL2—multiple sclerosis	0.000109	0.00194	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	0.000109	0.00194	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—LINGO1—multiple sclerosis	0.000108	0.00193	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CXCL10—multiple sclerosis	0.000107	0.0019	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CNR1—multiple sclerosis	0.000105	0.00187	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCR1—multiple sclerosis	0.000105	0.00186	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL13—multiple sclerosis	0.000105	0.00186	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL13—multiple sclerosis	0.000104	0.00185	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCR1—multiple sclerosis	0.000104	0.00185	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CXCL10—multiple sclerosis	0.000104	0.00185	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL13—multiple sclerosis	0.000102	0.00182	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCR1—multiple sclerosis	0.000102	0.00182	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	0.000101	0.0018	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—IL2—multiple sclerosis	0.000101	0.00179	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	9.95e-05	0.00177	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.66e-05	0.00172	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TAGAP—multiple sclerosis	9.6e-05	0.00171	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CXCL10—multiple sclerosis	9.45e-05	0.00168	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCL5—multiple sclerosis	9.41e-05	0.00167	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TAGAP—multiple sclerosis	9.39e-05	0.00167	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL5—multiple sclerosis	9.2e-05	0.00164	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CCL5—multiple sclerosis	8.96e-05	0.00159	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	8.7e-05	0.00155	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	8.52e-05	0.00151	CbGpPWpGaD
Nadolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	8.51e-05	0.00151	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	8.51e-05	0.00151	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCR5—multiple sclerosis	8.48e-05	0.00151	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—S1PR1—multiple sclerosis	8.39e-05	0.00149	CbGpPWpGaD
Nadolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	8.33e-05	0.00148	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCR5—multiple sclerosis	8.29e-05	0.00147	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—S1PR1—multiple sclerosis	8.21e-05	0.00146	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GPC5—multiple sclerosis	8.17e-05	0.00145	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL5—multiple sclerosis	8.14e-05	0.00145	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—CCR5—multiple sclerosis	8.07e-05	0.00144	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GPC5—multiple sclerosis	7.99e-05	0.00142	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—IL2RA—multiple sclerosis	7.95e-05	0.00141	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—PTGER4—multiple sclerosis	7.91e-05	0.00141	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—SRM—multiple sclerosis	7.88e-05	0.0014	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	7.85e-05	0.0014	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—PTGER4—multiple sclerosis	7.74e-05	0.00138	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCR3—multiple sclerosis	7.64e-05	0.00136	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.64e-05	0.00136	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCR3—multiple sclerosis	7.48e-05	0.00133	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL3—multiple sclerosis	7.46e-05	0.00133	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCR2—multiple sclerosis	7.43e-05	0.00132	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL3—multiple sclerosis	7.43e-05	0.00132	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCR5—multiple sclerosis	7.33e-05	0.0013	CbGpPWpGaD
Nadolol—ABCB1—Allograft Rejection—TNF—multiple sclerosis	7.33e-05	0.0013	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL3—multiple sclerosis	7.3e-05	0.0013	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCR2—multiple sclerosis	7.27e-05	0.00129	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL2RA—multiple sclerosis	7.22e-05	0.00128	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—PTGER4—multiple sclerosis	7.19e-05	0.00128	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PTGER4—multiple sclerosis	7.15e-05	0.00127	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—RGS1—multiple sclerosis	7.14e-05	0.00127	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—PGR—multiple sclerosis	7.04e-05	0.00125	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—PTGER4—multiple sclerosis	7.03e-05	0.00125	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—RGS1—multiple sclerosis	6.98e-05	0.00124	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCR3—multiple sclerosis	6.94e-05	0.00123	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCR3—multiple sclerosis	6.91e-05	0.00123	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CNR1—multiple sclerosis	6.86e-05	0.00122	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CD28—multiple sclerosis	6.84e-05	0.00122	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCR3—multiple sclerosis	6.79e-05	0.00121	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—GPR65—multiple sclerosis	6.77e-05	0.0012	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.75e-05	0.0012	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCR2—multiple sclerosis	6.75e-05	0.0012	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCR2—multiple sclerosis	6.72e-05	0.00119	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CNR1—multiple sclerosis	6.71e-05	0.00119	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—POMC—multiple sclerosis	6.62e-05	0.00118	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—GPR65—multiple sclerosis	6.62e-05	0.00118	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCR2—multiple sclerosis	6.6e-05	0.00117	CbGpPWpGaD
Nadolol—ADRB1—GPCR ligand binding—CCL2—multiple sclerosis	6.48e-05	0.00115	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—POMC—multiple sclerosis	6.48e-05	0.00115	CbGpPWpGaD
Nadolol—ADRB2—GPCR ligand binding—CCL2—multiple sclerosis	6.34e-05	0.00113	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—POMC—multiple sclerosis	6.31e-05	0.00112	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CNR1—multiple sclerosis	6.23e-05	0.00111	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CNR1—multiple sclerosis	6.2e-05	0.0011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR1—multiple sclerosis	6.19e-05	0.0011	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL13—multiple sclerosis	6.19e-05	0.0011	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CXCL10—multiple sclerosis	6.18e-05	0.0011	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CNR1—multiple sclerosis	6.09e-05	0.00108	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR1—multiple sclerosis	6.05e-05	0.00108	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL13—multiple sclerosis	6.05e-05	0.00108	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CXCL10—multiple sclerosis	6.04e-05	0.00107	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—POMC—multiple sclerosis	5.73e-05	0.00102	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CXCL10—multiple sclerosis	5.61e-05	0.000998	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—CCL2—multiple sclerosis	5.6e-05	0.000997	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CXCL10—multiple sclerosis	5.58e-05	0.000993	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP24A1—multiple sclerosis	5.55e-05	0.000987	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—CYP27B1—multiple sclerosis	5.55e-05	0.000987	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CXCL10—multiple sclerosis	5.49e-05	0.000976	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCL5—multiple sclerosis	5.32e-05	0.000946	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCL5—multiple sclerosis	5.2e-05	0.000925	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—TYK2—multiple sclerosis	5.09e-05	0.000905	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—GPC5—multiple sclerosis	5.08e-05	0.000903	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CD86—multiple sclerosis	4.88e-05	0.000868	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL5—multiple sclerosis	4.83e-05	0.000859	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL5—multiple sclerosis	4.81e-05	0.000855	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—CCR5—multiple sclerosis	4.79e-05	0.000852	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL5—multiple sclerosis	4.72e-05	0.00084	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2RA—multiple sclerosis	4.72e-05	0.00084	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—CCR5—multiple sclerosis	4.69e-05	0.000833	CbGpPWpGaD
Nadolol—ADRB3—GPCR downstream signaling—IL2—multiple sclerosis	4.66e-05	0.000829	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2RA—multiple sclerosis	4.62e-05	0.000821	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—SPP1—multiple sclerosis	4.45e-05	0.000792	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL3—multiple sclerosis	4.41e-05	0.000784	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCR5—multiple sclerosis	4.35e-05	0.000774	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCR5—multiple sclerosis	4.33e-05	0.00077	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL3—multiple sclerosis	4.31e-05	0.000767	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2RA—multiple sclerosis	4.29e-05	0.000763	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2RA—multiple sclerosis	4.27e-05	0.000759	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCR5—multiple sclerosis	4.26e-05	0.000757	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PTGER4—multiple sclerosis	4.24e-05	0.000755	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL2—multiple sclerosis	4.23e-05	0.000753	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—RRM1—multiple sclerosis	4.21e-05	0.000748	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2RA—multiple sclerosis	4.19e-05	0.000746	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—PGR—multiple sclerosis	4.18e-05	0.000743	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PTGER4—multiple sclerosis	4.15e-05	0.000738	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCR3—multiple sclerosis	4.1e-05	0.000729	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—PGR—multiple sclerosis	4.09e-05	0.000727	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD28—multiple sclerosis	4.06e-05	0.000722	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCR3—multiple sclerosis	4.01e-05	0.000713	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR2—multiple sclerosis	3.99e-05	0.000709	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD28—multiple sclerosis	3.97e-05	0.000707	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—APOE—multiple sclerosis	3.94e-05	0.000701	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR2—multiple sclerosis	3.9e-05	0.000694	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.88e-05	0.00069	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.87e-05	0.000689	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.8e-05	0.000675	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—POMC—multiple sclerosis	3.74e-05	0.000666	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CNR1—multiple sclerosis	3.68e-05	0.000655	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—POMC—multiple sclerosis	3.66e-05	0.000651	CbGpPWpGaD
Nadolol—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	3.62e-05	0.000643	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CNR1—multiple sclerosis	3.6e-05	0.00064	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CD80—multiple sclerosis	3.56e-05	0.000633	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—POMC—multiple sclerosis	3.4e-05	0.000605	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—POMC—multiple sclerosis	3.38e-05	0.000602	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—CCL2—multiple sclerosis	3.33e-05	0.000592	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—POMC—multiple sclerosis	3.33e-05	0.000592	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CXCL10—multiple sclerosis	3.31e-05	0.000589	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—CCL2—multiple sclerosis	3.31e-05	0.000589	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—CCL2—multiple sclerosis	3.25e-05	0.000579	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CXCL10—multiple sclerosis	3.24e-05	0.000577	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—MAPK1—multiple sclerosis	3.24e-05	0.000576	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—TYK2—multiple sclerosis	3.02e-05	0.000537	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TYK2—multiple sclerosis	3.01e-05	0.000535	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—TYK2—multiple sclerosis	2.95e-05	0.000526	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD86—multiple sclerosis	2.9e-05	0.000515	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL5—multiple sclerosis	2.85e-05	0.000507	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD86—multiple sclerosis	2.83e-05	0.000504	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL5—multiple sclerosis	2.79e-05	0.000496	CbGpPWpGaD
Nadolol—ADRB1—GPCR downstream signaling—IL2—multiple sclerosis	2.77e-05	0.000492	CbGpPWpGaD
Nadolol—ADRB2—GPCR downstream signaling—IL2—multiple sclerosis	2.71e-05	0.000482	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—SPP1—multiple sclerosis	2.64e-05	0.00047	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—SPP1—multiple sclerosis	2.58e-05	0.00046	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCR5—multiple sclerosis	2.57e-05	0.000457	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2RA—multiple sclerosis	2.53e-05	0.00045	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCR5—multiple sclerosis	2.51e-05	0.000447	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL2—multiple sclerosis	2.51e-05	0.000447	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL2—multiple sclerosis	2.5e-05	0.000445	CbGpPWpGaD
Nadolol—ADRB3—Signaling by GPCR—IL6—multiple sclerosis	2.49e-05	0.000443	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2RA—multiple sclerosis	2.48e-05	0.000441	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL2—multiple sclerosis	2.46e-05	0.000437	CbGpPWpGaD
Nadolol—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.43e-05	0.000432	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—BCHE—multiple sclerosis	2.42e-05	0.00043	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MMP9—multiple sclerosis	2.37e-05	0.000421	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—APOE—multiple sclerosis	2.34e-05	0.000416	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—APOE—multiple sclerosis	2.29e-05	0.000407	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CD80—multiple sclerosis	2.11e-05	0.000376	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—STAT3—multiple sclerosis	2.11e-05	0.000374	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CD80—multiple sclerosis	2.07e-05	0.000368	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—POMC—multiple sclerosis	2.01e-05	0.000357	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—CCL2—multiple sclerosis	1.97e-05	0.00035	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—POMC—multiple sclerosis	1.96e-05	0.000349	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MYC—multiple sclerosis	1.96e-05	0.000348	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—TGFB1—multiple sclerosis	1.95e-05	0.000347	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—MAPK1—multiple sclerosis	1.92e-05	0.000342	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—CCL2—multiple sclerosis	1.92e-05	0.000342	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—MAPK1—multiple sclerosis	1.91e-05	0.00034	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—MAPK1—multiple sclerosis	1.88e-05	0.000335	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TYK2—multiple sclerosis	1.78e-05	0.000317	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TYK2—multiple sclerosis	1.75e-05	0.00031	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL2—multiple sclerosis	1.48e-05	0.000264	CbGpPWpGaD
Nadolol—ADRB1—Signaling by GPCR—IL6—multiple sclerosis	1.48e-05	0.000263	CbGpPWpGaD
Nadolol—ADRB3—Signaling Pathways—IL6—multiple sclerosis	1.47e-05	0.000262	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—APOE—multiple sclerosis	1.45e-05	0.000259	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL2—multiple sclerosis	1.45e-05	0.000258	CbGpPWpGaD
Nadolol—ADRB2—Signaling by GPCR—IL6—multiple sclerosis	1.45e-05	0.000257	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MMP9—multiple sclerosis	1.41e-05	0.00025	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MMP9—multiple sclerosis	1.37e-05	0.000244	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—STAT3—multiple sclerosis	1.25e-05	0.000222	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—POMC—multiple sclerosis	1.25e-05	0.000222	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—STAT3—multiple sclerosis	1.22e-05	0.000217	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MYC—multiple sclerosis	1.16e-05	0.000206	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—TGFB1—multiple sclerosis	1.16e-05	0.000206	CbGpPWpGaD
Nadolol—ABCB1—Metabolism—ALB—multiple sclerosis	1.14e-05	0.000202	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—MAPK1—multiple sclerosis	1.14e-05	0.000202	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MYC—multiple sclerosis	1.14e-05	0.000202	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—TGFB1—multiple sclerosis	1.13e-05	0.000202	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—MAPK1—multiple sclerosis	1.11e-05	0.000198	CbGpPWpGaD
Nadolol—ADRB1—Signaling Pathways—IL6—multiple sclerosis	8.73e-06	0.000155	CbGpPWpGaD
Nadolol—ADRB2—Signaling Pathways—IL6—multiple sclerosis	8.54e-06	0.000152	CbGpPWpGaD
